Chimerix stock: buy or sell?
June 26th, 2019
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States.
Should I buy Chimerix stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Chimerix stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Chimerix stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we found 1 rating published for CMRX stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
Chimerix stock analysis
Chimerix shares boosted 3.87% to $3.49 today.
Chimerix shares boosted 3.87% to $3.49 today. Since last May when CMRX stock price broke up the SMA200d line, it gained $0.62 (21.60%). CMRX is retaking the upward trend marking a new rising bottom heading to break out over $3.72. Since SMA50d and SMA100d crossed up on May/15, CMRX price slid a -4.64%.
Shares of Chimerix escalated a very good 2.95% this week. By mid May CMRX boosted an exceptional 10.86% in just one week. Late May CMRX collapsed a dreadful -5.88% in just one week.
Chimerix stock just marked a top under its last top. Athought it's not concerning right now, investors should be alerted as this could be a warning for future complications. Sliding under its previous bottom at would confirm the downtrend path. Since price and SMA40w lines crossed up early May, CMRX climbed $0.79 (29.26%).
Chimerix stock price history
Chimerix IPO was on April 11th, 2013 at $15.14 per share1. Since then, CMRX stock lost a -76.90%, with a yearly average of -12.80%.
1: Adjusted price after possible price splits or reverse-splits.
Chimerix stock historical price chart
CMRX stock reached 52-week highs on July at $5.04, and all-time highs 2015-08-05 with a price of 58.04.
Chimerix stock price target is $2.00How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. Currently, only 1 price prediction for Chimerix stock was published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Chimerix failed to meet the expectations of the experts and reported a terrifying EPS of $-0.29 per share when experts were expecting $-0.36.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Chimerix annual sales boosted a dazzling 60.57% to $7.22 million dollars from $4.49 marked in 2017. Likewise, its profit margin (compared to sales) rocketed to -962.78%, that is $-69.47 million.
|2013||$4.37 M||-||$-70.55 M-1614.4%||-|
|2014||$4.04 M||-7.55%||$-59.31 M-1468.1%||-15.93%|
|2015||$11 M||166.39%||$-117.37 M-1090.6%||97.89%|
|2016||$5.70 M||-47.02%||$-76.39 M-1339.7%||-34.92%|
|2017||$4.49 M||-21.19%||$-70.98 M-1579.5%||-7.08%|
|2018||$7.22 M||60.57%||$-69.47 M-962.8%||-2.13%|
Quarterly financial resultsChimerix posted $4.86 million in sales for 2018-Q4, a 1,218.16% improvement compared to previous quarter. Reported quarter earnings marked $-14.96 million with a profit margin of -307.48%. Profit margin climbed a 4,049.97% compared to previous quarter when profit margin was -4,357.45%. When comparing revenues to same quarter last year, Chimerix sales marked an amazing gain and boosted a 163.77%.
|2017-Q1||$1.08 M||-||$-17.75 M-1643.5%||-|
|2017-Q2||$0.68 M||-37.50%||$-16.68 M-2471.1%||-6.03%|
|2017-Q3||$0.90 M||32.89%||$-17.31 M-1930.0%||3.79%|
|2017-Q4||$1.84 M||105.57%||$-19.24 M-1043.3%||11.13%|
|2018-Q1||$0.79 M||-57.16%||$-19.83 M-2509.6%||3.06%|
|2018-Q2||$1.19 M||51.01%||$-18.61 M-1560.2%||-6.12%|
|2018-Q3||$0.37 M||-69.07%||$-16.08 M-4357.5%||-13.61%|
|2018-Q4||$4.86 M||1,218.16%||$-14.96 M-307.5%||-6.98%|
Chimerix ownershipWhen you are planning to invest in a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Chimerix, 2.47% of all outstanding shares are owned by its staff.
Bearish positions for CMRX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Chimerix:
|Market cap||$178.2 M||$2.4 B||$84.7 B||$377.3 B||$214.7 B|
|Total shares||51.1 M||51.4 M||1,270.0 M||2,660.0 M||2,570.0 M|
|Float shares||37.8 M||43.1 M||1,270.0 M||2,650.0 M||2,570.0 M|
|- Institutional holdings (%)||82.0%||85.4%||82.6%||69.2%||78.3%|
|- Insider holdings (%)||2.5%||14.9%||0.7%||0.1%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$3.36 - $3.60|
|Average true range||$0.21|
|50d mov avg||$3.19|
|100d mov avg||$2.66|
|200d mov avg||$2.97|
Chimerix performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose Emergent Biosolutions, Gilead Sciences, , Merck, NewLink Genetics, NanoViricides, SIGA Technologies and Vical as the bechmarking frame for Chimerix stock.